Neal D. Shore, MD, FACS
Director, CPI, Carolina Urologic Research Center
Chief Medical Officer, Urology/Surgical Oncology
Myrtle Beach, SC
Neal D. Shore, MD, FACS, is the medical director for the Carolina Urologic Research Center and the chief medical officer, Urology/Surgical Oncology, GenesisCare, US, and he practices with Atlantic Urology Clinics in Myrtle Beach, SC. A graduate of Duke University and Duke University Medical School, Dr Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his general surgery/urology training at New York Hospital-Cornell Medical Center and Memorial Sloan Kettering Cancer Center in New York, NY.
Dr Shore has conducted more than 350 clinical trials focusing mainly on genitourinary oncology. He serves on the boards of Duke Global Health Institute, the Society of Urologic Oncology, and the Bladder Cancer Advocacy Network. He is a past president of the Large Urology Group Practice Association. He is a founder of both CUSP Clinical Trials Consortium and DASHKO (large urology practices data registries). He serves as the national urology research director for GenesisCare, US. He is the co-chair of the American Urological Association (AUA) International Prostate Cancer Forum and has served on the AUA Male Health and AUA Data committees, the Society for Immunotherapy of Cancer Task Force for Prostate Cancer and Bladder Cancer, and the Bladder Cancer Advocacy Network Bladder Cancer Think Tank. He is also a fellow of the American College of Surgeons.
Dr Shore has more than 250 peer-reviewed publications and numerous book chapters. He serves on the editorial boards of Reviews in Urology, Urology Times, Cancer Therapy Advisory (formerly known as Chemotherapy Advisor), OncLive, Urology Practice, and World Journal of Urology. He is the academic editor of PLOS ONE and the editor of Everyday Urology-Oncology Insights. He performs peer reviews for The Lancet Oncology, The New England Journal of Medicine, European Urology, The Journal of Urology, Urology, BJUI, Prostate Cancer and Prostatic Diseases, and numerous other high-impact scientific journals.